Skip to main content
. Author manuscript; available in PMC: 2017 Jan 19.
Published in final edited form as: Leukemia. 2015 Dec 21;30(5):1025–1032. doi: 10.1038/leu.2015.346

Figure 5. Peripheral blood absolute blast and neutrophil count of patient treated with 5-azacitidine and sorafenib.

Figure 5

The patient was treated continuously with sorafenib 400 mg twice daily beginning on Day 1, and with 5-azacitidine 75 mg/meter-squared IV daily for 7 days during the time periods indicated by black bars. At each of the indicated time points, the cellular fraction from the peripheral blood was analyzed for the presence of the FLT3/ITD mutation.